Ocular Therapeutix, Inc. – NASDAQ:OCUL
Ocular Therapeutix stock price today
$12.14
+3.70
+43.84%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Ocular Therapeutix stock price monthly change
+3.81%
month
Ocular Therapeutix stock price quarterly change
+3.81%
quarter
Ocular Therapeutix stock price yearly change
+87.56%
year
Ocular Therapeutix key metrics
Market Cap | 1.32B |
Enterprise value | 364.03M |
P/E | -5.13 |
EV/Sales | 7.06 |
EV/EBITDA | -5.88 |
Price/Sales | 7.80 |
Price/Book | 11.36 |
PEG ratio | N/A |
EPS | -1.10 |
Revenue | 59.65M |
EBITDA | -89.09M |
Income | -115.26M |
Revenue Q/Q | 10.02% |
Revenue Y/Y | 15.42% |
Profit margin | -137.96% |
Oper. margin | -152.75% |
Gross margin | 91.18% |
EBIT margin | -152.75% |
EBITDA margin | -149.35% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOcular Therapeutix stock price history
Ocular Therapeutix stock forecast
Ocular Therapeutix financial statements
| Jun 2023 | 15.18M | -20.68M | -136.19% |
|---|---|---|---|
| Sep 2023 | 14.95M | -516K | -3.45% |
| Dec 2023 | 14.80M | -29.22M | -197.41% |
| Mar 2024 | 14.71M | -64.84M | -440.69% |
| Mar 2024 | 14.71M | -64.84M | -440.69% |
|---|---|---|---|
| Sep 2025 | 24.52M | -11.39M | -46.48% |
| Oct 2025 | 18.99M | -29.37M | -154.62% |
| Dec 2025 | 19.63M | -31.02M | -157.97% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 122558000 | 119.47M | 97.48% |
|---|---|---|---|
| Sep 2023 | 162384000 | 154.53M | 95.16% |
| Dec 2023 | 252060000 | 160.92M | 63.85% |
| Mar 2024 | 538947000 | 130.96M | 24.3% |
| Jun 2023 | -20.07M | -1.99M | 9.64M |
|---|---|---|---|
| Sep 2023 | -7.73M | -259K | 57.11M |
| Dec 2023 | -17.27M | -459K | 102.98M |
| Mar 2024 | -33.88M | -255K | 321.22M |
Ocular Therapeutix alternative data
| Aug 2023 | 274 |
|---|---|
| Sep 2023 | 274 |
| Oct 2023 | 274 |
| Nov 2023 | 274 |
| Dec 2023 | 274 |
| Jan 2024 | 274 |
| Feb 2024 | 274 |
| Mar 2024 | 267 |
| Apr 2024 | 267 |
| May 2024 | 267 |
| Jun 2024 | 267 |
| Jul 2024 | 267 |
Ocular Therapeutix other data
20.52%
-31.16%
of OCUL is owned by hedge funds
78
-38
16.95M
-22.82M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 1538461 | 0 |
| Jan 2024 | 0 | 44513 |
| Feb 2024 | 930851 | 44139 |
| May 2024 | 0 | 23900 |
| Aug 2024 | 0 | 22712 |
| Nov 2024 | 0 | 28339 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HEIER JEFFREY S. officer: Chief Scientific Officer | Common Stock | 2,948 | $9.01 | $26,561 | ||
Sale | KAISER PETER officer: Chief Development Offi.. | Common Stock | 2,897 | $9.01 | $26,102 | ||
Sale | NAYAK SANJAY officer: Chief Strategy Officer | Common Stock | 1,814 | $9 | $16,326 | ||
Sale | DUGEL PRAVIN director, officer.. | Common Stock | 20,680 | $9.01 | $186,327 | ||
Sale | NAYAK SANJAY officer: Chief Strategy Officer | Common Stock | 1,832 | $9.02 | $16,525 | ||
Sale | DUGEL PRAVIN director, officer.. | Common Stock | 20,880 | $9.02 | $188,338 | ||
Sale | NAYAK SANJAY officer: Chief Strategy Officer | Common Stock | 2,274 | $5.84 | $13,280 | ||
Sale | DUGEL PRAVIN director, officer.. | Common Stock | 21,626 | $5.79 | $125,215 | ||
Purchase | SUMMER ROAD LLC 10 percent owner | Common Stock, $0.0001 par value per share | 930,851 | $7.52 | $7,000,000 | ||
Sale | WHITE CHRISTOPHER G officer: Chief Business Officer | Common Stock | 5,910 | $4.86 | $28,723 |
| Patent |
|---|
Application Filling date: 16 Feb 2022 Issue date: 14 Jul 2022 |
Application Filling date: 16 Feb 2022 Issue date: 14 Jul 2022 |
Application Filling date: 25 Feb 2022 Issue date: 30 Jun 2022 |
Application Filling date: 13 Dec 2021 Issue date: 16 Jun 2022 |
Grant Utility: Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine Filling date: 23 Sep 2021 Issue date: 17 May 2022 |
Grant Utility: Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine Filling date: 23 Sep 2021 Issue date: 5 Apr 2022 |
Application Filling date: 23 Sep 2021 Issue date: 24 Mar 2022 |
Application Filling date: 24 Mar 2021 Issue date: 7 Oct 2021 |
Application Filling date: 5 Feb 2021 Issue date: 19 Aug 2021 |
Application Filling date: 24 Apr 2020 Issue date: 29 Oct 2020 |
| Quarter | Transcript |
|---|---|
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 8 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 6 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Antony Mattessich (1967) Pres, Chief Executive Officer & Director | $1,030,000 |
Dr. Michael H. Goldstein M.M., M.D., M.B.A. (1967) Pres of Ophthalmology & Chief Medical Officer | $661,150 |
| Mr. Philip C. Strassburger (1960) Gen. Counsel | $282,610 |
EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026
Ocular Is Now Thoroughly Derisked
Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough
Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Ocular Therapeutix: I Still Don't See The Need
Ocular Therapeutix: A Promising Turnaround Play
Next Round Of Financing Will Be Transformational For Ocular Therapeutix
-
What's the price of Ocular Therapeutix stock today?
One share of Ocular Therapeutix stock can currently be purchased for approximately $12.14.
-
When is Ocular Therapeutix's next earnings date?
Unfortunately, Ocular Therapeutix's (OCUL) next earnings date is currently unknown.
-
Does Ocular Therapeutix pay dividends?
No, Ocular Therapeutix does not pay dividends.
-
How much money does Ocular Therapeutix make?
Ocular Therapeutix has a market capitalization of 1.32B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.49% to 58.44M US dollars.
-
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix, Inc. is traded on the NASDAQ under the ticker symbol "OCUL".
-
What is Ocular Therapeutix's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ocular Therapeutix?
Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the following people:
- Mr. Antony Mattessich Pres, Chief Executive Officer & Director(age: 58, pay: $1,030,000)
- Dr. Michael H. Goldstein M.M., M.D., M.B.A. Pres of Ophthalmology & Chief Medical Officer(age: 58, pay: $661,150)
- Mr. Philip C. Strassburger Gen. Counsel(age: 65, pay: $282,610)
-
How many employees does Ocular Therapeutix have?
As Jul 2024, Ocular Therapeutix employs 267 workers.
-
When Ocular Therapeutix went public?
Ocular Therapeutix, Inc. is publicly traded company for more then 11 years since IPO on 25 Jul 2014.
-
What is Ocular Therapeutix's official website?
The official website for Ocular Therapeutix is ocutx.com.
-
Where are Ocular Therapeutix's headquarters?
Ocular Therapeutix is headquartered at 24 Crosby Drive, Bedford, MA.
-
How can i contact Ocular Therapeutix?
Ocular Therapeutix's mailing address is 24 Crosby Drive, Bedford, MA and company can be reached via phone at +7 813574000.
Ocular Therapeutix company profile:
Ocular Therapeutix, Inc.
ocutx.comExchange:
NASDAQ
Full time employees:
267
Industry:
Biotechnology
Sector:
Healthcare
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
24 Crosby Drive
Bedford, MA 01730
Bedford, MA 01730
CIK: 0001393434
ISIN: US67576A1007
CUSIP: 67576A100
